Viatris is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit dip.
These stocks arguably deserve more respect from investors.
Viatris has underperformed the broader market over the past year, and analysts remain cautious about the stock's prospects.
The S&P 500 Index ($SPX ) (SPY ) Thursday closed up +0.51%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.85%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.16%. US stock indexes...
The S&P 500 Index ($SPX ) (SPY ) this morning is up +0.32%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.13%. US stock indexes this morning...
The S&P 500 Index ($SPX ) (SPY ) this morning is down -0.04%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.12%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.27%. US stock indexes this...
/CNW/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the launch in Canada of PrGlatiramer Acetate Injection 20 mg/mL for...
The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.63%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.20%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.99%. Stocks on Monday...
Investors can collect a high yield with Viatris, but is it a risky payout to rely on?
These companies aren't popular on the market right now, but income investors will like them.